Bias translation: The final frontier?

Area of Science:

• Pharmacology
• Biochemistry
• Drug Discovery

Background:

• Biased signaling is an inherent property of G protein-coupled receptor (GPCR) allosteric modulation.
• This phenomenon is expected from both natural and synthetic agonists and is frequently observed in agonist discovery projects.
• Biased signaling can be a beneficial or detrimental characteristic of potential drug candidates.

Purpose of the Study:

• To review the challenges in translating in vitro detected biased GPCR signaling to in vivo systems.
• To discuss the difficulties in predicting the therapeutic value of biased signaling due to translation failures.
• To explore novel strategies for improving the translation of biased signaling for therapeutic exploitation.

Main Methods:

• Review of existing literature on GPCR signaling and biased agonism.
• Analysis of the complexities in translating in vitro findings to in vivo pharmacological outcomes.
• Discussion of current and emerging methodologies for assessing and predicting in vivo efficacy of biased ligands.

Main Results:

• Biased signaling is a ubiquitous feature of GPCRs, arising from their allosteric function.
• The translation of in vitro identified biased signaling to in vivo efficacy is problematic and hinders therapeutic prediction.
• Current methods face challenges in accurately predicting the in vivo consequences of biased signaling observed in vitro.

Conclusions:

• Biased signaling is an integral aspect of GPCR pharmacology that must be considered in drug development.
• Overcoming the in vitro to in vivo translation gap is crucial for harnessing the therapeutic potential of biased GPCR agonists.
• Further research into novel predictive models and experimental approaches is needed to effectively exploit biased signaling mechanisms.